Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 803 participants.
Also called NCT01926782
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 803 participants
- Sponsor
- Registry
-
NCT01926782
-
- Other papers using this trial's data
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Hungary, Israel, Norway, Slovakia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01926782. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-03-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Statin
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct01926782- Content hash
4c5d7e8de6b8443b10c119143dd92348e171d7e86bfbababbe547f9cd8df5ba5